Conditions & Recovery · Cancer Health — Science · June 15, 2026

Fixed-Duration Triplet Therapy Demonstrates Efficacy for Patients with Relapsed/Refractory CLL

Adding Jaypirca to Venclexta and Rituxan for two years improves progression-free survival for patients with chronic lymphocytic leukemia.

Originally published by Cancer Health — Science. We curate and add context; they did the reporting.

Related learning